| Abstrakt: |
A recent study conducted by researchers at Tianjin Medical University Cancer Institute and Hospital in China has found that a molecule called Siglec-15, which is expressed on macrophages and tumor cells, may contribute to immunosuppression and poor prognosis in patients with non-metastatic lung adenocarcinoma. The study analyzed samples from 135 patients and found that Siglec-15 expression was independent of PD-L1 expression, another immune checkpoint molecule. Siglec-15-positive macrophages were associated with a higher risk of recurrence and the formation of an immunosuppressive microenvironment. The researchers suggest that Siglec-15 could be a potential target for improving cancer immunotherapy in patients who do not respond to anti-PD-L1 therapy. [Extracted from the article] |
